CLINICAL TRIAL

The Aortix device is an investigational device that is being evaluated in a clinical trial in the United States and Australia.

Currently Enrolling

The Aortix CRS Pilot Study (NCT04145635) is currently enrolling patients admitted to the hospital with a primary diagnosis of acute decompensated heart failure.
For more information on the study see
https://clinicaltrials.gov/ct2/show/NCT04145635
The Aortix™ device is currently in the research and development phase and is not available for sale in any country.
Caution: Investigational Device. Limited by Federal Law to Investigational Use.

Links

HomeClinical TrialsTeamNewsCareersReferencesDisclaimer & Terms of UseContact

LATEST NEWS

May 2021
Press Release
Procyrion Announces Successful First-in-Human Cases in Cardiorenal Syndrome (CRS) Patients with Aortix™ Percutaneous Mechanical Circulatory Support Device
August 2019
Press Release
Procyrion Names Av Edidin, Ph.D., as Senior Vice President of Development and Manufacturing
July 2019
Press Release
Procyrion Receives FDA Breakthrough Device Designation for Aortix™ System

ABOUT US

Procyrion is a team of experienced life science entrepreneurs, engineers, cardiologists, and heart failure specialists.

Our dedicated team is working to address the unmet clinical needs of heart failure patients through the development of a safe and innovative percutaneous mechanical circulatory support (pMCS) device.

Copyright © 2020 Procyrion, Inc.
Disclaimer & Terms of Use
Aortix™ is for investigational use only and is not for sale in the United States.